ERBB2 and breast carcinoma: The final PFS data confirmed that abemaciclib dosed on a continuous schedule in combination with a nonsteroidal AI provided statistically significant increases in median PFS and ORR as an initial treatment for postmenopausal women with HR+, HER2− advanced breast cancer.